{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:01Z","timestamp":1793656621183,"version":"4.5.1"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Pneumococcal conjugate vaccines (PCVs) have substantially reduced the global burden of\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    infections in children, yet serotype replacement and variability in immunogenicity continue to challenge long-term effectiveness. The recent introduction of the 20-valent vaccine (PCV20), which adds seven serotypes to those covered by PCV13, represents an important advance as these additional serotypes\u2014such as 8, 10A, 11A, 12F, 15B, 22F, and 33F\u2014are now recognized as significant contributors to invasive and noninvasive pneumococcal disease. To evaluate the potential and limitations of PCV20, we conducted a systematic literature search across PubMed, Scopus, and Web of Science through July 2025, supplemented by manual reference screening, including randomized trials, observational studies, systematic reviews, meta-analyses, and official reports from WHO, CDC, EMA, and FDA. Current evidence indicates that PCV20 elicits broadly noninferior immune responses compared to PCV13, though weaker responses have been observed for specific serotypes, notably 3, 6B, 9V, 19A, and 23F. Mathematical models suggest PCV20 could prevent thousands of additional pneumococcal cases annually compared with PCV13 or PCV15, but other analyzes predict increased breakthrough infections, particularly under reduced-dose regimens. The vaccine\u2019s effectiveness may also be limited by the potential for new serotype replacement, and concerns persist regarding its performance in 2 + 1 or 1 + 1 schedules, with regulatory agencies currently approving only the 3 + 1 regimen. These findings highlight PCV20 as a promising step in pneumococcal prevention but not a definitive solution. Continued surveillance, real-world effectiveness studies, and accelerated development of next-generation higher-valency vaccines will be essential to sustain and expand protection against pneumococcal disease in children.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1707345","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:33:31Z","timestamp":1767681211000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["PCV20 in pediatric pneumococcal prevention: expanded coverage, remaining challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Nicola","family":"Principi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Argentiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/14712598.2018.1384462","article-title":"Development of pneumococcal vaccines over the last 10 years","volume":"18","author":"Principi","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3390\/vaccines9040305","article-title":"Pneumococcal disease prevention: are we on the right track","volume":"9","author":"Principi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B3","article-title":"Streptococcus pneumoniae","volume-title":"StatPearls","author":"Dion","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5863\/1551-6776-21.1.27","article-title":"A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens","volume":"21","author":"Daniels","year":"2016","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3390\/bioengineering9120774","article-title":"Conjugation mechanism for pneumococcal glycoconjugate vaccines: classic and emerging methods","volume":"9","author":"Morais","year":"2022","journal-title":"Bioengineering (Basel)"},{"key":"B6","article-title":"Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease\u2013United States, 1998-2003","volume":"54","year":"2005","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-024-00977-4","article-title":"Cost-effectiveness of PCV20 to prevent pneumococcal disease in the pediatric population: A german societal perspective analysis","volume":"13","author":"Ta","year":"2024","journal-title":"Infect Dis Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2257426","DOI":"10.1080\/21645515.2023.2257426","article-title":"Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population","volume":"19","author":"Lytle","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3390\/vaccines11081369","article-title":"Estimating the clinical and economic impact of switching from the 13-valent pneumococcal conjugate vaccine (PCV13) to higher-valent options in Greek infants","volume":"11","author":"Warren","year":"2023","journal-title":"Vaccines"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3390\/vaccines11071168","article-title":"Estimating the cost-effectiveness of switching to higher-valency pediatric pneumococcal conjugate vaccines in the United Kingdom","volume":"11","author":"Wilson","year":"2023","journal-title":"Vaccines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00828-8","article-title":"Assessing public health impact of four pediatric pneumococcal conjugate vaccination strategies in the Netherlands","volume":"12","author":"Wilson","year":"2023","journal-title":"Infect Dis Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3390\/vaccines12111279","article-title":"The health and economic effects of PCV15 and PCV20 during the first year of life in the US","volume":"12","author":"Ilic","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01108-3","article-title":"Delayed transition to 20-valent pneumococcal conjugate vaccine in pediatric national immunization programs: forgone public health and economic benefit","volume":"14","author":"Perdrizet","year":"2025","journal-title":"Infect Dis Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30110-8","article-title":"Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study","volume":"5","author":"Savulescu","year":"2017","journal-title":"Lancet Respir Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30297-X","article-title":"Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study","volume":"19","author":"Lo","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/microorganisms11071816","article-title":"Systematic literature review of the epidemiological characteristics of pneumococcal disease caused by the additional serotypes covered by the 20-valent pneumococcal conjugate vaccine","volume":"11","author":"M\u00e9roc","year":"2023","journal-title":"Microorganisms"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1402795","article-title":"Serotype distribution of invasive pneumococcal disease from countries of the WHO Africa, Americas, Eastern Mediterranean, South-East Asia, and Western Pacific regions: a systematic literature review from 2010 to 2021","volume":"12","author":"Fletcher","year":"2024","journal-title":"Front Public Health"},{"key":"B18","doi-asserted-by":"publisher","first-page":"126219","DOI":"10.1016\/j.vaccine.2024.126219","article-title":"Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: A cross-sectional study","volume":"42","author":"Candeias","year":"2024","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac376","article-title":"Nasopharyngeal carriage of pneumococcus in children in england up to 10 years after 13-valent pneumococcal conjugate vaccine introduction: persistence of serotypes 3 and 19A and emergence of 7C","volume":"227","author":"Tiley","year":"2023","journal-title":"J Infect Dis"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2017.11.085","article-title":"Invasive pneumococcal disease in children under 16 years of age: Incomplete rebound in incidence after the maximum effect of PCV13 in 2012\/13 in Germany","volume":"36","author":"Weinberger","year":"2018","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)70044-7","article-title":"Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study","volume":"15","author":"Waight","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"126310","DOI":"10.1016\/j.vaccine.2024.126310","article-title":"Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines","volume":"42","author":"King","year":"2024","journal-title":"Vaccine"},{"key":"B23","unstructured":"Vaxcyte announces positive topline results from VAX-24 infant phase 2 dose-finding study"},{"key":"B24","unstructured":"Vaxcyte advances VAX-31 infant phase 2 dose-finding study with first participants receiving VAX-31 optimized dose"},{"key":"B25","doi-asserted-by":"publisher","first-page":"126310","DOI":"10.1016\/j.vaccine.2024.126310","article-title":"Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines","volume":"42","author":"King","year":"2024","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200003000-00003","article-title":"Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children","volume":"19","author":"Black","year":"2000","journal-title":"Pediatr Infect Dis J"},{"key":"B27","first-page":"1","article-title":"Recommendations for theproduction and control pf pneumococcal conjugatevaccineess","volume":"927","year":"2005","journal-title":"WHO Tech Rep Ser"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70822-9","article-title":"Serotype-specific effectiveness and correlates ofprotection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study","volume":"14","author":"Andrews","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2013.07.023","article-title":"Community-acquired pneumonia in children","author":"Cardinale","year":"2013","journal-title":"Early Hum Dev"},{"key":"B30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.pcl.2012.12.007","article-title":"Otitis media","volume":"60","author":"Pichichero","year":"2013","journal-title":"Pediatr Clin North Am"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.prrv.2011.12.001","article-title":"Streptococcus pneumoniae \u2013 a review of carriage, infection, serotype replacement and vaccination","volume":"13","author":"Mehr","year":"2012","journal-title":"Paediatr Respir Rev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2545032","DOI":"10.1080\/21645515.2025.2545032","article-title":"Approaches to assess new pneumococcal vaccines for immunogenicity, development and licensure","volume":"21","author":"Ganaie","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318199f8ef","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"B34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3390\/vaccines13050498","article-title":"The new era of pneumococcal vaccination in adults: what is next","volume":"13","author":"Ozisik","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1091908","article-title":"Interactions of conjugate vaccines and co-administered vaccines","volume":"12","author":"Findlow","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41541-023-00715-w","article-title":"Emerging vaccine strategies against the incessant pneumococcal disease","volume":"8","author":"Duke","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B37","doi-asserted-by":"publisher","first-page":"ofae220","DOI":"10.1093\/ofid\/ofae220","article-title":"Immunogenicity of current and next-generation pneumococcal conjugate vaccines in children: current challenges and upcoming opportunities","volume":"11","author":"Feemster","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: A review","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-3027","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers","volume":"126","author":"Yeh","year":"2010","journal-title":"Pediatrics"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit428","article-title":"Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial","volume":"57","author":"Dagan","year":"2013","journal-title":"Clin Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.008","article-title":"Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany","volume":"28","author":"Kieninger","year":"2010","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants","volume":"43","author":"Senders","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004300","article-title":"Phase 3 safety and immunogenicity study of a three-dose series of twenty-valent pneumococcal conjugate vaccine in healthy infants and toddlers","volume":"43","author":"Korbal","year":"2024","journal-title":"Pediatr Infect Dis J"},{"key":"B44","unstructured":"Product monograph\u2014PREVNAR 20"},{"key":"B45","unstructured":"Prescribing information. PREVNAR 20\u00ae (pneumococcal 20-valent conjugate vaccine), suspension for intramuscular injection"},{"key":"B46","unstructured":"European public assessment report (EPAR). Prevenar 20 (previously Apexxnar)"},{"key":"B47","unstructured":"Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): 20-valent pneumococcal conjugate vaccine (PCV20) for children aged <2 years"},{"key":"B48","unstructured":"Prevenar 20: EPAR medicine overview"},{"key":"B49","unstructured":"Vaccination Shedue for Pneumococcal disease"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00706-5","article-title":"Invasive pneumococcal disease 3 years after introduction of a reduced 1\u2009+\u20091 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study","volume":"24","author":"Bertran","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1017\/S095026881800198X","article-title":"Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK","volume":"146","author":"Wasserman","year":"2018","journal-title":"Epidemiol Infect"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01123-4","article-title":"PCV13-serotype breakthrough pneumococcal disease in infants receiving high-valency conjugate vaccines: population-level modeling in France","volume":"14","author":"Bakker","year":"2025","journal-title":"Infect Dis Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2335323","article-title":"Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2 + 1 dosing regimen","volume":"23","author":"Ryman","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccin Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.12.015","article-title":"Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data","volume":"36","author":"Lipsitch","year":"2018","journal-title":"Vaccine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.12.021","article-title":"Associations between geographic region and immune response variations to pneumococcal conjugate vaccines in clinical trials: A systematic review and meta-analysis","volume":"92","author":"Choe","year":"2020","journal-title":"Int J Infect Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000081","article-title":"The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity","volume":"33","author":"Park","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30660-1","article-title":"Making sense of differences in pneumococcal serotype replacement","volume":"19","author":"Lewnard","year":"2019","journal-title":"Lancet Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1707345\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:33:38Z","timestamp":1767681218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1707345\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":58,"alternative-id":["10.3389\/fimmu.2025.1707345"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1707345","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1707345"}}